Skip to main content
Fig. 5 | BMC Endocrine Disorders

Fig. 5

From: The effects of SGLT2 inhibitors on metabolic phenotype and FGF-21 expression from the adipose tissue and the liver are less pronounced in ob/ob mice

Fig. 5

Baseline expression of FGF-21 and the effects of dapagliflozin administration in lean and ob/ob mice. A. At baseline, higher expression of FGF-21 was found in ob/ob compared to lean mice in all considered tissues except BAT. B and C. Effects of dapagliflozin treatment on FGF-21 expression in SAT, VAT and BAT in ob/ob and lean mice. Analysis of FGF-21 mRNA expression in lean and ob/ob mice following administration of dapagliflozin showed that the SGLT2i administration was associated with a significant increase in gene expression (expressed as fold change) in VAT of lean mice (B), whereas gene expression was unaffected by the treatment in ob/ob mice (C). D, E and F. Dapagliflozin affects hepatic FGF-21 only in lean mice. The SGLT2i administration promoted a significant increase in liver FGF-21 gene expression (D and E) and protein concentration (F) in lean but no ob/ob mice. BAT: brown adipose tissue; SAT: subcutaneous adipose tissue; VAT: visceral adipose tissue. *p < 0.05; **p < 0.01*

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us